Table 1 The correlation between MAPK8IP2 expression level and clinicopathological factors in PCa
From: MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer
Factors | Â | Low expression of MAPK8IP2 | High expression of MAPK8IP2 | P value |
|---|---|---|---|---|
n | Â | 249 | 250 | Â |
Age, n (%) | ≤60 | 118 (23.6%) | 106 (21.2%) | 0.303 |
> 60 | 131 (26.3%) | 144 (28.9%) |  | |
PSA(ng/ml), n (%) | < 4 | 217 (49.1%) | 198 (44.8%) | 0.181 |
≥4 | 10 (2.3%) | 17 (3.8%) |  | |
Gleason score, n (%) | 6-8 | 198 (39.7%) | 159 (31.8%) | < 0.001 |
9-10 | 51 (10.2%) | 91 (18.2%) | Â | |
T stage, n (%) | T2 | 116 (23.6%) | 73 (14.8%) | < 0.001 |
T3-T4 | 128 (26.0%) | 175 (35.5%) | Â | |
N stage, n (%) | N0 | 181 (42.5%) | 166 (39%) | 0.002 |
N1 | 25 (5.9%) | 54 (12.7%) | Â | |
M stage, n (%) | M0 | 229 (50%) | 226 (49.3%) | 0.623 |
M1 | 1 (0.2%) | 2 (0.4%) | Â | |
Primary therapy outcome, n (%) | CR | 183 (41.8%) | 158 (36.1%) | 0.048 |
PD/SD/PR | 41 (9.4%) | 56 (12.8%) | Â | |
Race, n (%) | Asian | 4 (0.8%) | 8 (1.7%) | 0.522 |
Black or African American | 29 (6%) | 28 (5.8%) | Â | |
White | 206 (42.6%) | 209 (43.2%) | Â | |
Residual tumor, n (%) | R0 | 175 (37.4%) | 140 (29.9%) | 0.009 |
R1 | 61 (13%) | 87 (18.6%) | Â | |
R2 | 3 (0.6%) | 2 (0.4%) | Â | |
Zone of origin, n (%) | Central Zone | 3 (1.1%) | 1 (0.4%) | 0.174 |
Overlapping / Multiple Zones | 46 (16.7%) | 80 (29.1%) | Â | |
Peripheral Zone | 64 (23.3%) | 73 (26.5%) | Â | |
Transition Zone | 4 (1.5%) | 4 (1.5%) | Â |